Re:Covid: Remdesivir 'has little or no effect' on survival, ...
by fspeech on Friday October 16, 2020 @02:52PM
(#24803825)
I wish antivirals are trialed with a different end point: reduction in viral load. This can likely be done definitively and a lot faster as well. Deaths caused by ARDS may be triggered by a virus but it doesn't follow that clearing the virus would cure one of ARDS. We really need a pill form of the antiviral and give that to people much earlier in the disease course. A pill is possible in this case as a Remdesivir analog https://www.statnews.com/pharmalot/2020/08/24/nih-gilead-rem...
[ Parent
| on HN ]
Re:Covid: Remdesivir 'has little or no effect' on survival, ...
by lbeltrame on Friday October 16, 2020 @05:40PM
(#24805316)
Lilly and Regeneron's monoclonal antibodies use exactly that as primary endpoint. Unfortunately, most of them are e.v., with exception of one formulation by Regeneron, which is subcutaneous.